Amgen Astellas BioPharma is a joint venture between Amgen, one of the world’s largest independent biotechnology companies and Astellas Pharma, a leading Tokyo-based R&D-oriented global pharmaceutical company. It began operations on October 1, 2013, to provide breakthrough-science-based medicines to help address unmet medical needs of patients in Japan and received approval for its first product Repatha® (evolocumab) Injection in Japan from the Ministry of Health, Labour and Welfare on January 22, 2016. Amgen Astellas BioPharma will become a wholly-owned Amgen affiliate as soon as 2020.
For Amgen and Astellas Pharma histories, please refer to the following websites.
Astellas Pharma: https://www.astellas.com/en/corporate/about/history.html